Tools for Practice Outils pour la pratique


#364 Facing the Evidence in Acne, Part II: Oral Antibiotics


CLINICAL QUESTION
QUESTION CLINIQUE
How effective are oral antibiotics in treating acne of at least mild-moderate severity?


BOTTOM LINE
RÉSULTAT FINAL
Approximately 17% of patients achieve “success” on oral minocycline versus 9% on placebo at 12 weeks.  Oral antibiotics reduce acne lesion count by 10-24% more than placebo. Evidence of the efficacy of adding oral antibiotics to topical agents (example: retinoids, benzoyl peroxide) is limited. Efficacy appears similar between individual antibiotics. Discontinuations due to adverse events are comparable to placebo.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • Five systematic reviews1-5 (10-25 randomized controlled trials [RCTs], 165-4521 patients) of oral antibiotics (95% tetracyclines), mild to severe acne. After ~12-24 weeks:
    • Total lesion count (percent absolute reduction):
      • Oral antibiotic=10-24% reduction versus placebo1-5 (example: 33% versus 23% [placebo]).4
      • Oral antibiotic + benzoyl peroxide + retinoid (topical)=35-44% reduction versus placebo alone.2,5
      • Oral antibiotics versus topical clindamycin: Not statistically different.2,4
    • Inflammatory lesion count (percent absolute reduction):
      • Oral antibiotic=13-27% reduction versus placebo1-4 (example: 46% versus 33% [placebo]).4
      • Oral antibiotic + benzoyl peroxide + retinoid (topical)=37% reduction versus placebo alone.2
      • Oral antibiotics versus topical clindamycin: Not statistically different.2,4
    • Investigators global assessment of success:4
      • 17% (minocycline) versus 9% (placebo); number needed to treat (NNT)=13.
    • Discontinuation due to adverse events:
      • No difference versus placebo.2,5
        • Exception: One systematic review: minocycline 9% versus 1% placebo (included regimens up to 3 times usual dose).4
  • No difference between different oral antibiotics in terms of efficacy or adverse event discontinuations.3,4
  • Limitations: Patient-assessed outcomes not reported in systematic reviews, inadequate efficacy reporting of adding oral antibiotics to topical agents versus topical agents alone; few RCTs comparing oral antibiotics to topical agents; inadequate data on antimicrobial resistance.

CONTEXT
CONTEXTE
  • Guidelines generally recommend:
    • Adding oral antibiotics to topical treatments for moderate-to-severe acne or acne resistant to topical treatments.6-8
    • ~12-week course of oral antibiotics, then reassessment.6-8 UK guidelines suggest considering a second 12-week course if acne improved but not completely clear.8
  • Topical retinoids and oral tetracyclines contraindicated during pregnancy;8 contraception discussion recommended if of childbearing age.


Ronald Maier April 27, 2024

Adding oral antibiotic in addition to topical treatment likely beneficial for patients

gregory Stroh April 29, 2024

Prefer a far more liberal approach in using roaccutane


Latest Tools for Practice
Derniers outils pour la pratique

#364 Facing the Evidence in Acne, Part II: Oral Antibiotics

How effective are oral antibiotics in treating acne of at least mild-moderate severity?
Read Lire 0.25 credits available Crédits disponibles

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

#362 Facing the Evidence in Acne, Part I: Oral contraceptives and spironolactone in females

How effective are combined oral contraceptives (COC) and spironolactone for treating acne of at least mild-moderate severity in females?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Allison Paige MD CCFP
  • Sasha Katwaroo PharmD candidate
  • Brianne Desrochers PharmD candidate
  • Jamie Falk PharmD

1. Mavranezouli I, Daly CH, Welton NJ, et al. Br J Dermatol. 2022; 187(5):639–49.

2. Huang CY, Chant IJ, Bolick N, et al. Ann Fam Med. 2023; 21(4):358–69.

3. Koo BS, Petersen TD, Kimball AB. J Am Acad Dermatol. 2014; 71(3):450–9.

4. Garner SE, Eady A, Bennett C, et al. Cochrane Database Syst Rev. 2012; 8: CD002086.

5. National Institute for Health and Care Excellence (NICE). Acne vulgaris: management options for moderate to severe acne – network meta-analysis. Available at: https://www.nice.org.uk/guidance/ng198/evidence/f1-management-options-for-moderate-to-severe-acne-network-metaanalyses-pdf-9144159955; Updated June 2021. Accessed December 12, 2023.

6. Zaenglein AL, Pathy AL, Schlosser BJ, et al. J Am Acad Dermatol. 2016; 74:945-73.

7. Asai Y, Baibergenova A, Dutil M, et al. CMAJ. 2016; 188(2):118-126.

8. National Institute for Health and Care Excellence (NICE). Acne vulgaris: management. Available at: https://www.nice.org.uk/guidance/ng198/resources/acne-vulgaris-management-pdf-66142088866501; Accessed December 12, 2023.

Authors do not have any conflicts of interest to declare.